The board of directors of Nasdaq-listed Anixa Biosciences has approved the purchase of bitcoin as a reserve asset. The company also reaffirmed its ongoing share buyback program. CEO Amit Kumar said the decision on bitcoin is another approach to prudent financial management that can achieve higher shareholder value. It is reported that Anixa Biosciences is a biotechnology company focused on the treatment and prevention of cancer.